Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone + tamoxifen in metastatic male breast cancer
NL-OMON51371Completed
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of testosterone and tamoxifen in breast cancer, sponsored by University Medical Center Groningen. Primary endpoint: Safety profile. Started Nov 2022; status: completed.
02
Drugs
testosteronetamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON51371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51371.